Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKM543)

Drug Name

Acecainide Drug Info

Synonyms

N-Acetylprocainamide; Acekainid; 32795-44-1; Acecainida; Acecainidum; NAPA; N-Acetyloprokainamid; Acecainide [INN]; Acekainid [Polish]; 4'-((2-(Diethylamino)ethyl)carbamoyl)acetanilide; Acecainidum [INN-Latin]; Acecainida [INN-Spanish]; N-Acetyloprokainamid [Polish]; UNII-910Q707V6F; CHEBI:60728; Benzamide, 4-(acetylamino)-N-(2-(diethylamino)ethyl)-; BRN 2868559; CHEMBL1097; MLS000069490; KEECCEWTUVWFCV-UHFFFAOYSA-N; 4-acetamido-N-[2-(diethylamino)ethyl]benzamide; 910Q707V6F; SMR000059070; ACETANILIDE,; NAPA; Acecainide hydrochloride; ASL-601; Acetylprocainamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 4342
ChEBI ID: CHEBI:60728
CAS Number: CAS 32795-44-1
TTD Drug ID: DMKM543
VARIDT Drug ID: DR00526
INTEDE Drug ID: DR2295

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[4]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[5]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[4]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[5]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[6]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[7]
Dyclonine	DMU6OFP	Pain	MG30-MG3Z	Approved	[3]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[8]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[9]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[10]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[10]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[11]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[10]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[12]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[10]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[10]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[13]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[10]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Opener	[2]
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Blocker	[3]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000315)
2	Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40.
3	Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
4	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
5	Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
6	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
7	Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
8	From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
9	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
12	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
13	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.